Breadcrumb Home IMPAACT News IMPAACT News News March 2025 Announcements IMPAACT 2017 (MOCHA) Data Supports European Commission’s Authorization of Vocabria and Rekambys in Adolescents March 2025 Announcements News from CROI 2025 February 2025 Announcements Announcing the 2025 IMPAACT Early Career Investigators Search Enter a search term. Filter Topics AllAnnouncementsMeetingsSpotlight SeriesStudy Results Date All2025202420232022202120202019201820162014 Sort Date AscDate Desc Submit Search Showing 18 news items. March 2024 Announcements Study Results Meetings News from CROI 2024 December 2023 Study Results Announcements IMPAACT P1115 Team Publishes Two-Year Findings for Newborns Who Received Very Early Treatment for HIV August 2023 Announcements Study Results Data from IMPAACT 2019 Contribute to FDA Approval of a Once-Daily Dispersible HIV Drug for Young Children February 2022 Study Results IMPAACT Shares Study Results in CROI 2022 Oral Presentations February 2022 Study Results IMPAACT P1107 Team Presents First Known Case of a Woman with HIV Remission February 2022 Study Results IMPAACT Shares Study Results at CROI 2022 Poster Presentations July 2021 Study Results IMPAACT 2019 Results Released June 2020 Study Results IMPAACT P1093 Informs FDA Decision to Approve First-ever Dolutegravir Dispersible Tablet for Treatment of Children living with HIV March 2020 Study Results IMPAACT 2010 Primary Results Released March 2020 Study Results IMPAACT 2001 Primary Results Released Pagination Current page 1 Page 2 Next page Next
March 2025 Announcements IMPAACT 2017 (MOCHA) Data Supports European Commission’s Authorization of Vocabria and Rekambys in Adolescents
December 2023 Study Results Announcements IMPAACT P1115 Team Publishes Two-Year Findings for Newborns Who Received Very Early Treatment for HIV
August 2023 Announcements Study Results Data from IMPAACT 2019 Contribute to FDA Approval of a Once-Daily Dispersible HIV Drug for Young Children
February 2022 Study Results IMPAACT P1107 Team Presents First Known Case of a Woman with HIV Remission
June 2020 Study Results IMPAACT P1093 Informs FDA Decision to Approve First-ever Dolutegravir Dispersible Tablet for Treatment of Children living with HIV
